Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01F (MK-1084 Combinations in KRAS G12C NSCLC)
ChiCTR2600124257Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of calderasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Objective response rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600124257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124257.